Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Diamyd Medical ABOSTO:DMYD B -0.39%41 Days Payable is 870.99 as of May. 2026, which is 25% above its 10-year median of 696.14. GuruFocus rates OSTO:DMYD B with a GF Score™ of 41/100 and a GF Value™ of kr13.67 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 704 Biotechnology companies, Diamyd Medical AB ranks better than 87.64% on this metric.
The historical rank and industry rank for Diamyd Medical AB's Days Payable or its related term are showing as below:
OSTO:DMYD B'
s Days Payable Range Over the Past 10 Years
Min: 314.55 Med: 696.14 Max: 1359.45
Current: 1137.48
During the past 13 years, Diamyd Medical AB's highest Days Payable was 1359.45. The lowest was 314.55. And the median was 696.14.
OSTO:DMYD B's Days Payable is ranked better than 87.64% of 704
companies
in the Biotechnology industry
Industry Median: 112.715
vs OSTO:DMYD B: 1137.48
Diamyd Medical AB's Days Payable
declined
from May. 2025 (1,148.52) to May. 2026 (870.99).
It may suggest that Diamyd Medical ABaccelerated paying its suppliers.
The historical data trend for Diamyd Medical AB's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:DMYD B vs VRTX, REGN, RVMD: Days Payable Comparison
For the Biotechnology subindustry, Diamyd Medical AB's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Diamyd Medical AB Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Diamyd Medical AB's Days Payable distribution charts can be found below:
* The bar in red indicates where Diamyd Medical AB's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Diamyd Medical AB's Days Payable for the fiscal year that ended in Aug. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Diamyd Medical AB (OSTO:DMYD B) has a Days Payable of 870.99 as of May. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Diamyd Medical AB and its competitors. This is 25% above median its historical median of 696.14. Over the past decade, Diamyd Medical AB's Days Payable has ranged from 314.55 to 1,359.45. According to the industry distribution chart, Diamyd Medical AB ranks #87 out of 704 companies in the Biotechnology industry, placing it in the top 12.4%.
Is Diamyd Medical AB's Days Payable too high?
Diamyd Medical AB's current Days Payable of 870.99 is 25% above median its 10-year median of 696.14. Over the past 10 years, this metric has ranged from a low of 314.55 to a high of 1,359.45. The Biotechnology industry median Days Payable is 112.72. Diamyd Medical AB's value of 870.99 is 672.7% above this industry median. Based on the distribution chart, Diamyd Medical AB ranks #87 out of 704 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Diamyd Medical AB has a GF Score™ of 41/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Diamyd Medical AB's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Diamyd Medical AB ranks #87 out of 704 companies for Days Payable. This places Diamyd Medical AB in the top 12% of its industry — outperforming the majority of peers. The industry median Days Payable is 112.72. Diamyd Medical AB's value of 870.99 is 672.7% above this benchmark. Historically, Diamyd Medical AB's own Days Payable has ranged from 314.55 to 1,359.45 over the past decade. While the company's 10-year median is 696.14 vs. the industry median of 112.72, Diamyd Medical AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.72, based on 704 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Diamyd Medical AB's current Days Payable of 870.99 is 672.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Diamyd Medical AB and its competitors. For the Biotechnology industry, the median Days Payable is 112.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Diamyd Medical AB's current Days Payable is 870.99, which is 25% above median its own 10-year median of 696.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diamyd Medical AB stock overvalued right now?
Based on GuruFocus' analysis, Diamyd Medical AB (OSTO:DMYD B) is currently considered Possible Value Trap. The stock's GF Value™ is kr13.67, compared to a current price of kr1.01 — trading 92.6% below its estimated fair value. The current Days Payable is 870.99, which is 25% above median its 10-year median of 696.14 and 672.7% above the Biotechnology industry median of 112.72. Diamyd Medical AB's overall GF Score™ is 41/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Diamyd Medical AB (OSTO:DMYD B), the current Days Payable is 870.99 as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Diamyd Medical AB (OSTO:DMYD B) Overvalued in 2026?
Based on GuruFocus' analysis, Diamyd Medical AB stock appears to be undervalued.
The current stock price of kr1.01 is trading 92.6% below its estimated GF Value™ of kr13.67.
GuruFocus considers Diamyd Medical AB to be Possible Value Trap.
Key valuation signals for OSTO:DMYD B:
Days Payable: 870.99 (25% above median its 10-year median of 696.14)
GF Value™: kr13.67 vs. price of kr1.01 (92.6% below fair value)
Industry Position: 672.7% above the Biotechnology median (#87 of 704)
No single metric tells the full story. See the OSTO:DMYD B stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Diamyd Medical AB develops precision medicine therapies for the prevention and treatment of type 1 diabetes using antigen-based immune technology. Its product candidate, Diamyd (rhGAD65/alum), is an antigen-specific immunomodulatory therapy that aims to preserve endogenous insulin production in individuals carrying the HLA DR3-DQ2 genotype and is being evaluated in the registrational Phase 3 DIAGNODE-3 trial in Stage 3 type 1 diabetes, as well as in the DiaPrecise trial in children with Stage 1 and Stage 2 type 1 diabetes. The Company's activities include clinical development, antigen-specific immunotherapy and in-house manufacturing of recombinant GAD65.
41GF Score
Get the complete analysis for OSTO:DMYD B
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:DMYD B has been successfully added to your 
